Given the demonstrated efficacy of arginine deprivation therapy with pegargiminase in other cancer types and the identification of a significant patient subgroup with ASS1 deficiency in esophageal adenocarcinoma, clinical trials are warranted to evaluate the potential benefit of this therapy in this context. Here, ASS1 is linked to esophageal adenocarcinoma.